Based on these findings, the currently available treatment for MM targets both the malignant cells and the MM niche, through the inclusion of proteasome or HDAC inhibitors, which act on stromal cells, osteoclasts, and angiogenesis (42, 43). The gene discussed is HDAC9; the disease is Miyoshi myopathy.